Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Core Insights - Replimune Group, Inc. has granted inducement equity awards to 34 newly hired non-executive employees as a material inducement for their employment [2][3] - The inducement awards consist of non-qualified stock options for 58,240 shares and restricted stock units for 116,680 shares, with an exercise price of $14.25 per share [2] - The options have a 10-year term and vest over four years, while the restricted stock units vest in approximately four equal annual installments starting February 15, 2026 [2][3] Company Overview - Replimune Group, Inc. is a clinical stage biotechnology company founded in 2015, focused on developing novel oncolytic immunotherapies to transform cancer treatment [4] - The company's proprietary RPx platform utilizes a potent HSV-1 backbone aimed at maximizing immunogenic cell death and inducing a systemic anti-tumor immune response [4] - RPx product candidates are designed to work synergistically with established and experimental cancer treatment modalities, allowing for versatile development options [4]